Phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite, and a vinca-alkaloid (study L00070 IN 308 B0).

Trial Profile

Phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite, and a vinca-alkaloid (study L00070 IN 308 B0).

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Vinflunine (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Pierre Fabre
  • Most Recent Events

    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Status changed from active, no longer recruiting to completed as result presented at 51st Annual Meeting of the American Society of Clinical Oncology.
    • 19 Aug 2013 Planned end date changed from 1 Aug 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top